Phase II High Pulse Dose Clinical Trial of Orally Administered ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 23 May 2013
At a glance
- Drugs Givinostat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 31 Jan 2012 Actual patient number (1) added as reported by ClinicalTrials.gov.
- 31 Jan 2012 Planned end date changed from 1 Dec 2009 to 1 Jul 2010 as reported by ClinicalTrials.gov.
- 31 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.